Jump to Navigation

Facebook Connect

User login

NLA Meetings

Meeting Info

Meeting Program -  Click here to download the 2015 Scientific Sessions Meeting Program.

Venue:
Palmer House Hotel

For reservations, please call 1-877-865-5321 and ask for the National Lipid Association's room rate. A special room rate starting at $229 per night plus tax has been arranged. This group rate will be available until May 19, 2015, or until the room block is fi­lled. Please make your reservation early as we do anticipate the room block will sell out.

To learn more about the hotel, please visit palmerhousehiltonhotel.com

Thursday, June 11, 2015

Session I- NLA Expert Panel Recommendations

3:45 - 4:00 PM Presidential Welcome & Introductions Terry A. Jacobson, MD, FNLA
4:00 - 4:30 PM NLA Recommendations for Patient-Centered Management of Dyslipidemia

Carl E. Orringer, MD, FNLA

4:30 - 5:00 PM Audience Discussion and Faculty Q&A
5:00 - 5:30 PM NLA Recommendations for Management of Special Populations

Terry A. Jacobson, MD, FNLA

5:30 - 6:00 PM Audience Discussion and Faculty Q&A
6:00 - 7:00 PM Welcome Reception in Exhibit Hall

Friday, June 12, 2015

Keynote Session- Clinical Implications of Novel Targets and Emerging Therapies

7:00 - 7:40 AM Breakfast in Exhibit Hall
7:40 - 7:55 AM Business Meeting
7:55 - 8:00 AM Morning Notes
6:30 - 7:45 AM Non-CME Workshop: Navigating the NLA Annual Summary of Clinical Lipidology 2015: Present and Future Harold E. Bays, MD, FNLA
8:00 - 8:30 AM Emerging Lipid Modifying Therapies

James M. McKenney, PharmD, FNLA

8:30 - 9:00 AM New Evidence & Outcomes- Information Lipidologists Need to Know

Philip J. Barter MD, PhD

9:00 - 9:30 AM Q&A Panel
9:30 - 10:00 AM Break in Exhibit Hall

Session III- Controversies in Statin Safety

10:00 - 10:30 AM Statins and Risk for Diabetes Mellitus

Kevin C. Maki, PhD, CLS, FNLA

10:30 - 11:00 AM Risk Underlying Statin-Induced Myopathy

Robert S. Rosenson, MD

11:00 - 11:30 AM Perspectives on Statins and Cognitive Impairment

Vera A. Bittner, MD, MSPH, FNLA

11:30 - 12:00 Q&A Panel
12:00 - 12:15 PM Business Meeting
12:15 - 1:15 PM Lunch in Exhibit Hall
1:15 - 2:15 PM Abstracts Session

Session IV- Lifestyle Management to Reduce Cardiovascular Risk

2:15 - 2:24 PM Role of Exercise and Diet in AHA/ACC Guidelines for Lifestyle Management

Robert H. Eckel, MD, FNLA

2:45 - 3:15 PM Lifestyle Guidelines- A Practical Implementation with Patients

Sonja L. Connor, MS, RD, FNLA

3:15 - 3:45 PM Q&A Panel
3:45 - 4:00 PM Business Meeting
4:00 - 4:15 PM Break

Session V- Treatment Strategies in Obesity Management

4:15 - 4:45 PM AACE Obesity Management Guidelines & an Actionable Diagnostic Framework

W. Timothy Garvey, MD

4:45 - 5:15 PM Weight Management through Pharmacotherapy

Harold E. Bays, MD, FNLA

5:15 - 5:45 PM The Role and Long-Term Effects of Metabolic Surgery

J. Christopher Eagon, MD

5:45 - 6:15 PM Q&A Panel

Saturday, June 13, 2015

Session VI- Special Symposium: Controversies in Assessing CVD Risk

7:00 - 7:40 AM Breakfast in Exhibit Hall
7:40 - 7:55 PM Business Meeting
7:55 - 8:00 AM Morning Notes
8:00 - 8:25 AM Perspectives on AHA/ ACC Guidelines for Risk Assessment

Donald M. Lloyd-Jones, MD, ScM

8:25 - 8:50 AM Practical Use of Other Risk Calculators

Paul M. Ridker, MD

8:50 - 9:10 AM Q&A Panel
9:10 - 9:40 AM Break in Exhibit Hall

Session VII- Consensus and Controversies in Clinical Lipid Management

9:40 - 10:05 AM 2013 ACC-AHA Guidelines: Increasing Science Supports the Paradigm Shift

Neil J. Stone, MD, FNLA

10:05 - 10:30 AM Considering the Evidence of Epidemiological and Genetic Studies in Addition to Randomized Clinical Trials

Kevin C. Maki, PhD, FNLA

10:30 - 10:50 AM Q&A Panel
10:50 - 11:15 AM NLA Business Meeting
11:15 - 12:15 Lunch in Exhibit Hall

Session VIII- Understanding Hypertension Management Guidelines

12:15 - 12:40 PM Clinical Controversies in Hypertension Management – A Review of the Guidelines

Kenneth A. Jamerson, MD, FAHA, FASH

12:40 - 1:05 PM Impact of Hypertension Threshold and Goals on Special Populations

Keith C. Ferdinand, MD, FNLA

1:05 - 1:20 PM Q&A Panel

Session IX- Comprehensive Management of Diabetes

1:20 - 1:45 AM Controversies in Diabetes Guidelines

Janet B. McGill, MD

1:45 - 2:10 PM Treating Diabetic Dyslipidemia: A Case Discussion

Kathleen L. Wyne, MD, PhD, FNLA

2:10 - 2:25 PM Q&A Panel
2:25 - 2:40 PM Business Meeting
2:40 - 2:55 PM Break

Session X- Case Discussions: Treatment Strategies for High Risk Populations

2:55 - 3:20 PM Managing the Patient with Residual Lipid Risk

Peter H. Jones, MD, FNLA

3:20 - 3:45 PM South Asian Ethnicity- Management and Associated Risk

Shoeb J. Sitafalwalla, MD

3:45 - 4:00 PM Q&A Panel

Session XI- Adherence Challenges and Strategies for the Practicing Clinician

4:00 - 4:25 PM Popular Weight Loss Diets: Mythology, Evidence and Your Practice

Penny Kris-Etherton, PhD, RD, FNLA

4:25 - 4:50 PM Medication Adherence: Patient Barriers, Provider Barriers, & Strategies for Improving Adherence

Lynne T. Braun, PhD, CNP, FNLA

4:50 - 5:30 PM Motivational Interviewing in the Prevention and Treatment of Chronic Illness

Kenneth A. Resnicow, PhD

5:30 - 5:45 PM Q&A Panel
6:00 - 7:00 PM Honors & Awards Ceremony and Convocation
7:30 - 10:30 PM Foundation of The National Lipid Association Event

Sunday, June 14, 2015

7:00 - 7:55 AM Breakfast
7:00 - 7:55 AM Non-CME Workshop: Publishing in the JCL

W. Virgil Brown, MD, FNLA

Session XII- Pediatric Dyslipidemia – Guidelines and Pharmacology Workshop

7:55 - 8:00 AM Program Introduction Don P. Wilson, MD, FNLA
8:00 - 8:20 AM Guidelines and Pharmacology for Pediatric Dyslipidemia

Stephen R. Daniels, MD, PhD, FNLA

8:20 - 8:40 AM Point-Counterpoint: Is Universal Screening and Treatment of Hypercholesterolemia in Children Justified?: Yes: The Evidence Supports Universal Screening and Treatment

Irwin Benuck, MD, PhD

8:40 - 8:55 AM Q&A
8:55 - 9:15 AM Point-Counterpoint: Is Universal Screening and Treatment of Hypercholesterolemia in Children Justified?: No: The Evidence Does Not Support Universal Screening and Treatment

Peter F. Belamarich, MD

9:15 - 9:30 AM Q&A
9:30 - 9:50 AM Pediatric Lipid Screening for Familial Hypercholesterolemia

Sarah D. deFerranti, MD, MPH

9:50 - 10:10 AM Combined Dyslipidemia in Childhood

Rae-Ellen W. Kavey, MD, MPH

10:10 - 10:20 AM Q&A Panel
10:20 - 11:00 AM Panel Discussion: Enhancing Provider Education on Pediatric Dyslipidemia

Piers R. Blackett, MD, FNLA
Stephen R. Daniels, MD, PhD, FNLA
Patrick E. McBride, MD, MPH
Pamela B. Morris, MD, FNLA
Elaine M. Urbina, MD

Session XII- Women’s Issues Workshop

7:55 - 8:00 AM Introduction

Robert A. Wild, MD, MPH, PhD, FNLA

8:00 - 8:15 AM Case Related to A Patient with Lp(a) and Women/Stroke Risk

Joyce L. Ross, MSN, CRNP, FNLA

8:15 - 8:40 AM A Patient with Lp(a) and Stroke Risk

Pamela B. Morris, MD, FNLA

8:40 - 9:00 AM Audience Participation and Panel Interaction
9:00 - 9:15 AM Case Related to Contraceptive Choices & Familial Hypercholesterolemia

Joyce L. Ross, MSN, CRNP, FNLA

9:15 - 9:40 AM Contraceptive Choices & Familial Hypercholesterolemia

James A. Underberg, MD, MS, FNLA

9:40 - 10:00 AM Audience Participation and Panel Interaction
10:00 - 10:15 AM Case Related to Menopause Management and Dyslipidemia

Joyce L. Ross, MSN, CRNP, FNLA

10:15 - 10:40 AM Menopause Management and Dyslipidemia

Robert A. Wild, MD, MPH, PhD, FNLA

10:40 - 11:00 AM Audience Participation and Panel Interaction

Session XII- Everyday Patient Cases- What to do After the Evidence? Workshop

8:00 - 8:15 AM Case: High Risk Patient with Premature Heart Disease

Kaye-Eileen Willard, MD

8:15 - 8:40 AM Evaluating Residual Risk and Long Term Management of the Young CHD Patient

Patrick M. Moriarty, MD, FNLA

8:40 - 9:00 AM Q&A Panel
9:00 - 9:15 AM Case: Dyslipidemia Patient with Nephrotic Syndrome

Kaye-Eileen Willard, MD

9:15 - 9:40 AM Risk Assessment and Clinical Management of the Patient with Nephrotic Syndrome

Edgar V. Lerma, MD, FNLA

9:40 - 10:00 AM Q&A Panel
10:00 - 10:15 AM Case: Cardiovascular Risks in the HIV Patient

Kaye- Eileen Willard, MD

10:15 - 10:40 AM Unique Characteristics of the HIV Infected Patient with Cardiovascular Disease

Daniel A. Duprez, MD, PhD, FNLA

10:40 - 11:00 AM Q&A Panel

Upon completion of the educational activity, participants should be able to:

Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses and registered dietitians with an interest in lipid management.

Type of Activity
Live Activity
Knowledge (Sessions I- X, XII Pediatric Dyslipidemia, XII Everyday Patient Cases)
Application (Sessions XI, Session XII Women's Issues)

CME credit provided by the National Lipid Association
Physicians
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Lipid Association designates this live activity for a maximum of 19.50 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 19 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.

American Academy of Family Physicians
This Live activity, 2015 National Lipid Association Annual Scientific Sessions, with a beginning date of 06/11/2015, has been reviewed and is acceptable for up to 19.00 Elective credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE credit provided by Postgraduate Institute for Medicine

Pharmacists

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Session I- Universal Activity Number 0809-9999-15-012-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Session II- Universal Activity Number 0809-9999-15-013-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (.15 CEUs) of the Accreditation Council for Pharmacy Education

Session III – Universal Activity Number 0809-9999-15-014-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Session IV– Universal Activity Number 0809-9999-15-015-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (.15 CEUs) of the Accreditation Council for Pharmacy Education

Session V – Universal Activity Number 0809-9999-15-016-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Session VI – Universal Activity Number 0809-9999-15-017-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education

Session VII – Universal Activity Number 0809-9999-15-018-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education

Session VIII – Universal Activity Number 0809-9999-15-019-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education

Session IX – Universal Activity Number 0809-9999-15-020-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education

Session X – Universal Activity Number 0809-9999-15-021-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education

Session XI – Universal Activity Number 0809-9999-15-022-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (.175 CEUs) of the Accreditation Council for Pharmacy Education

Session XII Pediatric Dyslipidemia – Universal Activity Number 0809-9999-15-024-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 3.0 contact hour(s) (.30 CEUs) of the Accreditation Council for Pharmacy Education

Session XII Women’s Issues – Universal Activity Number 0809-9999-15-025-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 3.0 contact hour(s) (.30 CEUs) of the Accreditation Council for Pharmacy Education

Session XII Everyday Patient Cases – Universal Activity Number 0809-9999-15-023-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 3.0 contact hour(s) (.30 CEUs) of the Accreditation Council for Pharmacy Education

Nursing
This educational activity for 19 contact hours is provided by the Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Session I- 2.0 credits; Session II- 1.5 credits; Session III- 2.0 credits; Session IV- 1.5 credits; Session V- 2.0 credits; Session VI- 1.1 credits; Session VII- 1.1 credits; Session VIII- 1.0 credits; Session IX- 1.0 credits; Session X- 1.0 credits; Session XI- 1.7 credits; Session XII: Pediatric Dyslipidemia- 3.0 credits; Session XII: Women’s Issues- 3.0 credits; Session XII: Everyday Patient Cases- 3.0 credits.  

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Educational Objectives
At the conclusion of this activity, registered nurses and nurse practitioners should be able to provide appropriate counsel for patients and their families.

At the conclusion of this activity, all participants should be able to:

Session I- NLA Expert Panel Recommendations

  • Define the National Lipid Association’s Recommendations for Patient-Centered Management of Dyslipidemia
  • Describe the NLA recommendations for management of dyslipidemias in special populations

Keynote Session- Clinical Implications of Novel Targets and Emerging Therapies

  • Describe the efficacy, safety, and mechanisms of action of novel lipid-targeted pharmacotherapies
  • Critically appraise current clinical trial results in order to apply evidence-based medicine into daily clinical practice
  • Assess the implications of ongoing lipid treatment outcomes  trials for the future clinical management of patients with dyslipidemia

Session III- Controversies in Statin Safety

  • Review the impact of statin therapy on glycemic control in diabetes and the risk of new onset diabetes in the statin treated patient
  • Review the risk and the  mechanisms  for  statin induced myopathy
  • Describe the evidence for the risk of cognitive impairment with statin treatment

Session IV- Lifestyle Management to Reduce Cardiovascular Risk 

  • Review the lifestyle recommendations in the 2013 ACC/AHA guidelines
  • Identify the  nutrient intake and food choices to meet these  guidelines

Session V- Treatment Strategies in Obesity Management

  • Describe the current guidelines on the diagnosis, management and treatment of obesity
  • Review the approved pharmacologic therapies for the treatment of obesity including their impacts on lipid metabolism
  • Identify the pros and cons of bariatric surgery for the treatment of obesity

Session VI- Special Symposium: Controversies in Assessing CVD Risk

  • Describe  the effectiveness of available risk assessment tools in predicting 10 year and lifetime CV risk
  • Compare and contrast the risk predictor tools in diverse patient populations

Session VII- Consensus and Controversies in Clinical Lipid Management

  • Evaluate the evidence-based approach to the 2013 ACC/AHA guidelines for the management of blood cholesterol in adults.
  • Compare and contrast the effectiveness of utilizing other scientific evidence in   the management decisions of dyslipidemia

Session VIII- Understanding Hypertension Management Guidelines

  • Evaluate the clinical implications of the 2013 Hypertension guidelines
  • Discuss the controversies and impact of the new hypertension guidelines on clinical management in special patient populations

Session IX- Comprehensive Management of Diabetes

  • Discuss the controversies in managing  type 2 diabetes mellitus using guideline recommendations and evidence-based treatment
  • Compare therapeutic options for the treatment of dyslipidemia in patients  with diabetes

Session X- Case Discussions: Treatment Strategies for High Risk Populations

  • Describe combination therapies for the management of complex lipid disorders and residual risk
  • Identify the potential roles that novel lipid therapies may play in reducing residual risk in patients with CVD
  • Discuss the management of dyslipidemia in special populations based on gender, culture, and ethnicity

Session XI- Adherence Challenges and Strategies for the Practicing Clinician

  • Review the scientific research relating to adherence to lipid-lowering therapies and the  impact on  treatment decisions
  • Implement strategies that  improve patient adherence and compliance  to lipid-modifying therapies
  • Outline the impact of various diets on short-term and long-term weight loss

Session XII- Pediatric Dyslipidemia – Guidelines and Pharmacology Workshop

  • Appraise treatment recommendations and evidence for screening, diagnosing and treating dyslipidemias in pediatric patients
  • Illustrate the importance of universal screening during childhood and cascade lipid screening of family members of known familial hypercholesterolemia (FH) patients

Session XII- Women’s Issues Workshop

  • Appraise the evidence for screening, diagnosing and treating FH in women of childbearing potential and during pregnancy
  • Explain the  CVD effects of menopausal hormone therapy (MHT)
  • Implement appropriate dyslipidemia management during menopause transition

Session XII- Everyday Patient Cases- What to do After the Evidence Workshop

  • Describe the identification and treatment  of residual risk in young patients with cardiovascular disease (CVD)
  • Discuss the appropriate lipid management strategies for patients with chronic kidney disease
  • Discuss the underlying CVD risk in patients with HIV

 

Criteria for Success:
Statements of credit will be awarded based on the participant´s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme.
For Pharmacists: Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure Statement:
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.

Commercial Support:
Full notification of commercial support will be provided in the activity syllabus.

Terry A. Jacobson, MD, FNLA

President, National Lipid Association
Director, Office of Health Promotion and Disease Prevention
Professor of Medicine
Emory University
Atlanta, GA
Diplomate, American Board of Clinical Lipidology

Kaye-Eileen Willard, MD, FNLA

President, Midwest Lipid Association
Chief of Department of Medicine
Medical Director, Chronic Disease Management
Wheaton Franciscan Healthcare, All Saints
Racine, WI
Diplomate, American Board of Clinical Lipidology

Carl E. Orringer, MD, FACC, FNLA

President-Elect, National Lipid Association
Associate Professor of Medicine
University of Miami
School of Medicine
Miami, FL
Diplomate, American Board of Clinical Lipidology

Laxmana M. Godishala, MD, FNLA

Clinical Assistant Professor
University of Minnesota Medical School
Edina, MN
Diplomate, American Board of Clinical Lipidology

Anne C. Goldberg, MD, FNLA

Associate Professor of Medicine
Washington University School of Medicine
St. Louis, MO
Diplomate, American Board of Clinical Lipidology

Robert A. Wild, MD, MPH, PhD, FNLA

Professor, Clinical Lipidology and Obstetrics and Gynecology
Oklahoma University Health Sciences Center
Oklahoma City, OK
Diplomate, American Board of Clinical Lipidology

Philip Barter, MD, PhD

Professor, University of New South Wales, Australia
President, International Atherosclerosis Society
New South Wales, Australia

Harold E. Bays, MD, FNLA

Medical Director/President
Louisville Metabolic and Atherosclerotic
Research Center
Louisville, KY
Diplomate, American Board of Clinical Lipidology

Peter F. Belamarich, MD

Associate Professor of Clinical Pediatrics
Albert Einstein College of Medicine
Medical Director, Pediatric Ambulatory Subspecialty Services,
The Children’s Hospital at Montefiore
Bronx, NY

Irwin Benuck, MD, PhD

Division Head, Community-Based Pediatrics
Professor of Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Vera A. Bittner, MD, MSPH, FNLA

Professor of Medicine
Section Head, Preventive Cardiology
University of Alabama at Birmingham
Birmingham, AL
Diplomate, American Board of Clinical Lipidology

Piers R. Blackett, MD, FNLA

Professor
University of Oklahoma Health Sciences Center
Oklahoma City, OK
Diplomate, American Board of Clinical Lipidology

Lynne T. Braun, PhD, CNP, FNLA

Professor of Nursing and Nurse Practitioner
Rush University Medical Center
Chicago, IL

Sonja L. Connor, MS, RD, FNLA

Associate Professor of Research
Department of Medicine
Oregon Health Sciences University
Portland, OR

Stephen R. Daniels, MD, PhD, FNLA

Chairman, Department of Pediatrics
University of Colorado School of Medicine
Pediatrician-in-Chief
L. Joseph Butterfield Chair in Pediatrics
Children's Hospital Colorado
Aurora, CO

Sarah D. De Ferranti, MD, MPH

Director, Preventive Cardiology Program
Assistant Professor of Pediatrics,
Harvard Medical School
Boston, MA

Daniel A. Duprez, MD, PhD, FNLA

Professor, Department of Medicine, Cardiovascular Division,
University of Minnesota
Donald and Patricia Garofalo Chair for Preventive Cardiology
Director of Research, Rasmussen Center for Cardiovascular Disease Prevention
Associate Director, Cardiovascular Clinical Trials Center
Minneapolis, MN

J. Christopher Eagon, MD

Associate Professor, Surgery
Division of General Surgery
Section of Minimally Invasive Surgery

Washington University School of Medicine
St. Louis, MO

Robert H. Eckel, MD, FNLA

Charles A. Boettcher Endowed Chair in Atherosclerosis
Professor of Medicine - Division of Endocrinology, Metabolism and Diabetes, and Cardiology
Professor of Physiology and Biophysics
Program Director, Adult General Clinical Research Center
Aurora, CO
Diplomate, American Board of Clinical Lipidology

Keith C. Ferdinand, MD, FNLA

Professor of Clinical Medicine
Tulane University Heart and Vascular Institute
New Orleans, LA

W. Timothy Garvey, MD

Professor and Chair
Department of Nutrition Sciences
School of Health Professions
Senior Scientist
Nutrition Obesity Research Center
Birmingham, AL

Kenneth A. Jamerson, MD

Professor, Internal Medicine
Frederick G.L. Huetwell Collegiate Professor of Cardiovascular Medicine
University of Michigan Medical School
Ann Arbor, MI 

Peter H. Jones, MD, FNLA

Associate Professor
Department of Medicine Center for Cardiovascular
 Disease Prevention
Baylor College of Medicine
Houston, TX
Diplomate, American Board of Clinical Lipidology

Rae-Ellen W. Kavey, MD

Pediatric Cardiologist
Rochester, NY

Penny Kris-Etherton, PhD, RD, FNLA

Distinguished Professor of Nutrition
The Pennsylvania State University
University Park, PA

Edgar V. Lerma, MD, FNLA

Clinical Professor of Medicine
University of Illinois at Chicago
Chicago, IL

Donald M. Lloyd-Jones, MD, ScM

Senior Associate Dean
Director, Northwestern University Clinical and Translational Sciences (NUCATS)
Institute Chair and Professor of Preventive Medicine
Northwestern University Feinberg School of Medicine
Chicago, IL

Kevin C. Maki, PhD, FNLA

Chief Science Officer
Midwest Center for Metabolic & Cardiovascular Research
Chicago, IL

Patrick E. McBride, MD, MPH

Professor of Medicine and Family Medicine,
Co-Director Preventive Cardiology,
Associate Dean, University of Wisconsin
Madison, WI

Janet B. McGill, MD

Professor, Medicine
Division of Endocrinology, Metabolism and Lipid Research
St. Louis, MO

James M. McKenney, PharmD, FNLA

CEO, National Clinical Research, Inc.
Manakin Sabot, VA

Patrick M. Moriarty, MD, FNLA

Professor, Department of Internal Medicine
Director, Division of Clinical Pharmacology and
Atherosclerosis/ Lipid Apheresis Center
University of Kansas Medical Center
Kansas City, KS

Pamela B. Morris, MD, FNLA

Director, Preventive Cardiology
Co-Director, Women’s Heart Care
Medical University of South Carolina
Charleston, SC

Kenneth Resnicow, PhD

Professor
Health Behavior & Health Education
School of Public Health
University of Michigan
Ann Arbor, MI

Paul M. Ridker, MD

Senior Physician, Brigham and Women's Hospital
Eugene Braunwald Professor of Medicine,
Harvard Medical School
Boston, MA

Robert S. Rosenson, MD

Director
Cardiometabolic Disorders
Mount Sinai Heart
Professor of Medicine (Cardiology)
Icahn School of Medicine
Mount Sinai
New York, NY
Diplomate, American Board of Clinical Lipidology

Joyce L. Ross, MSN, CRNP, FNLA

President, Northeast Lipid Association
Past-President, Preventive Cardiovascular Nurses Association
Consultative Education Specialist,
  Cardiovascular Risk Intervention
University of Pennsylvania Health System- Retired
Philadelphia, PA

Shoeb J. Sitafalwalla, MD

Medical Director
South Asian Cardiovascular Center
Division of Cardiovascular Disease
Advocate Lutheran General Hospital
Park Ridge, IL

Neil J. Stone, MD, FNLA

Bonow Professor of Medicine
Feinberg School of Medicine
Northwestern University
Suzanne and Milton Davidson Distinguished
Physician and Medical Director, Vascular Center
Bluhm Cardiovascular Institute
Northwestern Memorial Hospital
Chicago, IL
Diplomate, American Board of Clinical Lipidology

James A. Underberg, MD, MS, FNLA

Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for Prevention of Cardiovascular Disease
Director Bellevue Hospital Lipid Clinic
New York, NY
Diplomate, American Board of Clinical Lipidology

Elaine M. Urbina, MD

Director, Preventive Cardiology
Cincinnati Children's Hospital Medical Center
Cincinnati Children's Heart Institute, Division of Pediatric Cardiology
Cincinnati, OH

Don P. Wilson, MD, FNLA

Medical Director, Pediatric Cardiovascular Health
  and Risk Prevention Program
Cook Children’s Medical Center
Fort Worth, TX
Diplomate, American Board of Clinical Lipidology

Kathleen L. Wyne, MD, PhD, FNLA

Assistant Professor of Medicine
Weill Cornell Medical College
Houston, TX
Diplomate, American Board of Clinical Lipidology

Register for the 2015 Scientific Sessions

Must be logged in to see NLA member price

Personal Information

Contact Information

Which meetings or courses would you like to attend?

NLA Member Discount Rate up to 2015-05-12NLA Member Discount Rate after 2015-05-12Non-Member RateTrainee Rate*
*Trainees must register with .PDF form.
Scientific Sessions
June 11-14, 2015
Includes one admission badge to Exhibit Hall for all food functions.
$645.00 $675.00 $1150.00 $75.00
Masters in Lipidology Course
June 10-11, 2015
$750.00 $750.00 $1250.00 $395.00
NLA Lipid Academy
June 10-11, 2015
$550.00 $550.00 $950.00
2015 NLA Coding Course
June 11, 2015
$150.00 $200.00 $300.00
Foundation Event- Lipidpalooza at the House of Blues 195 x
Guest Pass- Exhibit Hall 175 x

Total

$0.00

Payment Information

2015 EXHIBITS

Plan now for your company to participate in the National Lipid Association’s Annual Scientific Sessions in Chicago. Our meeting provides you with a unique opportunity to reach our target audience of Lipidologists, Cardiologists, Endocrinologists, Primary Care Physicians and Allied Health Professionals involved in dyslipidemia management, as well as our distinguished board and faculty.

Our numerous sponsorship opportunities allow you to connect with our members in a whole new way, providing you with maximum return on your investment. The exhibit hall provides a unique setting for you and your company’s representatives to interact daily with attendees as they study the latest advances in their professions.

We look forward to your participation and seeing you in 2015!

Download Exhibit Prospectus

NLA- Annual Sessions Company Descriptions

Amgen Inc.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

www.amgen.com

 

AstraZeneca

AstraZeneca is focused on the discovery, development and commercialization of medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, and neuroscience diseases.

www.astrazeneca.com

 

Boston Heart Diagnostics

Boston Heart Diagnostics is enabling healthcare providers and patients to improve heart health and prevent disease with our integrated diagnostics, personalized reporting and lifestyle management solution.

www.bostonheartdiagnostics.com

 

Carlson Laboratories, Inc.

Carlson celebrates 50 years of providing you with natural-source E products, award-winning fish oils and the freshest, purest vitamins and nutritional supplements.

www.carlsonlabs.com

 

Genzyme

Genzyme discovers and delivers transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before. Visit www.genzyme.com.

 

Kowa Pharmaceuticals America, Inc.

Kowa Pharmaceuticals America, Inc. is focused in the area of cardiometabolic diseases and focuses its efforts on the successful commercialization of its current and near-term portfolio of pharmaceutical products, and business development activities. For more information about Kowa Pharmaceuticals America, visit www.kowapharma.com.

 

Merck

Today's Merck is a global healthcare leader working to help the world be well. 

www.merck.com

 

Sanofi and Regeneron

Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients’ needs. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.

www.regeneron.com

 

Synageva

Synageva is a biopharmaceutical company focused on the discovery, development, and commercialization of products for patients with rare diseases. Our pipeline programs include the lead program, Kanuma™ (sebelipase alfa) for lysosomal acid lipase deficiency (LAL D), SBC-103 for mucopolysaccharidosis IIIB (MPS IIIB), and SBC-105 for generalized arterial calcification of infancy (GACI) and other rare calcification diseases.

www.synageva.com

Lipidpalooza

Fundraising at the House of Blues

Saturday, June 13 | 7:30–10:30 PM

$195 per person

Join us at the House of Blues in downtown Chicago for an evening packed with music, food, and fun. Bring your family and support the Foundation of the National Lipid Association (FNLA), while enjoying today’s most popular songs, delicious food, and tasty drinks with colleagues and friends. FNLA board member and Chicago native Dr. Alan Brown and his band, This End Up, will provide the tunes for the evening! Take advantage of the complimentary photo booth to capture the unforgettable occasion and take home memories.

 

Meet in the Palmer House Hotel lobby at 7:00 pm for a walk to the House of Blues.

 


Non-CME Workshop/Symposium

Workshop: Navigating the NLA Annual Summary of Clinical Lipidology 2015: Present and Future

Friday, June 12
6:30 - 7:45 AM

Host:
Harold Bays, MD, FTOS, FACC, FACE, FNLA
Medical Director/President
L-MARC Research Center
Louisville, KY
Diplomate, American Board of Clinical Lipidology

The recently published NLA Annual Summary of Clinical Lipidology 2015 is an essential resource for the busy lipidologist. Its futuristic format presentation of "all-things-lipids" provides "one-stop-shopping" for the very latest in the comprehensive basics of Clinical Lipidology, and is applicable to both basic scientists and beginning clinicians alike. In this symposium, Dr. Harold Bays will provide insights to its genesis, its unique navigation format, exciting plans for future novel enhancements, as well as provide an opportunity for attendees to provide feedback and input to the upcoming 2016 edition.


Workshop: Publishing in the Journal of Clinical Lipidology

Sunday, June 14
7:00–7:55 AM

Host:
W. Virgil Brown, MD, FNLA
Charles Howard Candler Professor Emeritus
Emory University School of Medicine
Atlanta, GA
Diplomate, American Board of Clinical Lipidology

During the NLA Scientific Sessions, Dr. Virgil Brown, along with a representative from Elsevier, will be on hand for a non-CME workshop on tips for getting published in the Journal. To find out more about this session and to register, visit lipid.org/sessions. There is no additional cost to register for this non-CME Symposium; simply let us know your interest in participating on the registration form.

2015 SATELLITE SYMPOSIA GUIDELINES

The National Lipid Association (NLA) has established that independently developed and CME/CE certified satellite symposia held in conjunction with the scientific meetings of the NLA are valuable opportunities to provide continuing education for our members. In this regard, we are pleased to offer satellite symposia slots in conjunction with our 2015 Clinical Lipid Updates.

Satellite symposia address educational needs and performance gaps that complement the NLA scientific program agenda. They may include one or a number of speakers and may cover one or several topics addressing the educational gaps of lipid specialists.

The following deadlines and guidelines provide important information about holding a Satellite Symposium at the 2015 Clinical Lipid Updates and the process for completing a symposium proposal. Please contact the NLA business development department directly (contact below) should there be any questions or further information required. See you in 2015!

DOWNLOAD 2015 SATELLITE SYMPOSIA GUIDELINES 2015

Contact:
Amina Resheidat
Program Coordinator
904-309-6212

aresheidat@lipid.org

0
No votes yet

Coming Soon...

0
No votes yet



by Dr. Radut.